Nomura Holdings Inc I Mab Transaction History

Nomura Holdings Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.21 - $1.9 $452,642 - $710,761	-374,085 Reduced 94.21%	23,000 $43,000
Q3 2023 Nov 14, 2023	SELL	$1.18 - $3.06 $54,280 - $140,760	-46,000 Reduced 10.38%	397,085 $524,000
Q2 2023 Aug 14, 2023	SELL	$2.95 - $3.85 $82,349 - $107,472	-27,915 Reduced 5.93%	443,085 $1.32 Million
Q1 2023 May 15, 2023	BUY	$3.08 - $7.39 $92,378 - $221,648	29,993 Added 6.8%	471,000 $1.63 Million
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $6.99 Million - $10.6 Million	-2,172,207 Reduced 83.12%	441,007 $1.84 Million
Q3 2022 Nov 15, 2022	BUY	$4.01 - $12.34 $32,080 - $98,720	8,000 Added 0.31%	2,613,214 $10.5 Million
Q2 2022 Aug 15, 2022	BUY	$8.27 - $18.43 $21.5 Million - $48 Million	2,605,214 New	2,605,214 $28.3 Million
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $185,964 - $305,971	-4,107 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$57.18 - $84.43 $6,118 - $9,034	107 Added 2.68%	4,107 $292,000
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $191,440 - $335,800	4,000 New	4,000 $323,000

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.